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 Abstract 
 Objective: To provide the fi rst update on drug safety profi les 
and adverse drug reactions (ADRs) associated with fetal dis-
orders from the Swiss national ADR database. 
 Methods: We conducted a retrospective study using data 
from 202 pharmacovigilance reports on drug-associated fetal 
disorders from the Swiss national ADR database from 1990 to 
2009. Evaluated aspects included administrative information 
on the report, drug exposure, and disorders. 
 Results: The ADR reporting frequency on the topic of fetal 
disorders has increased during the last 20 years, from only 1 
report in 1991 to a maximum of 31 reports in 2008. Nervous 
system drugs were the most frequently reported drug group 
(40.2 % ) above all antidepressants and antiepileptics. The 
highest level of overall drug intake could be observed for the 
1 st trimester (85.4 % ), especially for the fi rst 6 weeks of preg-
nancy. The most frequently reported types of fetal disorders 
were malformations (68.8 % ), especially those of the muscu-
loskeletal and circulatory systems. A positive association was 
discovered between antiepileptics and malformations in gen-
eral and in particular of the circulatory system and the eye, 
ear, face, and neck. 
 Conclusions: The results suggest that the nervous system 
drug group bears an especially high risk for malformations. 
The most commonly identifi ed drug exposures can help 
focus pharmacoepidemiologic efforts in drug-induced birth 
defects. 
 Keywords:  Drug use;  fetal disorders;  pharmacovigilance; 
 pregnancy;  safety;  teratovigilance. 
 Introduction 
 Despite lingering safety questions, pregnant women may 
intentionally or inadvertently be exposed to various prescrip-
tion drugs for pregnancy and non-pregnancy indications. 
Current utilization studies that ascertain the most commonly 
used drugs in pregnancy are important for establishing priori-
ties in birth-defects research with major public health impli-
cations  [11] . 
 Studies conducted among pregnant women in the USA and 
in some European countries show exposure to high rates of 
prescription medications, including exposure to medications 
with known teratogenic potential  [1, 2, 7, 10, 16] . Engeland et 
al.  [7] found that among more than 100,000 pregnant women 
in Norway in 2004 – 2006, approximately 57 % received a 
prescription medication. Studies from France and Germany 
showed an even higher rate of more than 85 %  [6, 15] . 
 However, at the time of marketing, there exist little data 
on the safety of a drug used in pregnancy and adverse drug 
reactions (ADRs) on the fetus. Initial data on a drug ’ s safety 
profi le concerning its use during pregnancy are provided prior 
to marketing by reproductive toxicity studies in animals. Such 
studies are quite reliable for the detection of a drug ’ s terato-
genic potential because only few drugs that did not show a 
teratogenic effect in animals are later found to be teratogenic 
in humans. However, because of differences in the species ’ 
pharmacokinetic profi les, fi ndings about toxic doses in animals 
can only limitedly be extrapolated to humans. Furthermore, 
clinical trials in drug development generally exclude pregnant 
women for ethical reasons. 
 These factors increase the importance of ongoing risk 
assessment in the postmarketing phase. In fact, postmar-
keting observational studies have revealed associations 
between many commonly used drugs and various birth 
defects  [3, 4, 26] . 
 The aim of this study was to provide the fi rst update on 
the existing postmarketing pharmacovigilance data on drug-
associated fetal disorders from the Swiss national ADR 
database. 
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 Materials and methods 
 Data source 
 The Swiss national ADR database, called VigiFlow, contains ADR 
reports from the entirety of Switzerland ’ s approximately 7 million 
inhabitants. It is held by the national pharmacovigilance center 
run by the Swiss Agency for Therapeutic Products (Swissmedic), 
which is the central supervisory authority for therapeutic products 
in Switzerland. Swissmedic is a public service organization of the 
federal government and has its headquarters in Berne. Most of the 
reports are spontaneous (97 % ); others are sourcing from clinical 
studies. Reports on observed ADRs are sent by health-care profes-
sionals to one of the regional pharmacovigilance centers (RPVCs) 
located in Zurich, Basel, Berne, Lausanne, Geneva, and Lugano. The 
RPVCs register, classify, and evaluate the reports and enter them 
directly into VigiFlow. Moreover, reports on ADRs are collected 
by the pharmaceutical companies and sent directly to Swissmedic, 
which enters the incoming reports into VigiFlow. Every report 
entering VigiFlow is evaluated by a clinical reviewer and checked 
for quality and completeness. Swissmedic is closely involved in the 
World Health Organization (WHO) program for drug monitoring and 
its classifi cation system. For the classifi cation of ADR reports, sever-
al international standards, documents, and guidelines are used  [5, 13, 
21 – 23] (Table  1 ). All ADR reports in VigiFlow are directly submitted 
to WHO ’ s ADR database in Uppsala, Sweden (VigiBase). VigiFlow 
is compatible with the International Conference on Harmonisation 
Guideline E2B and complies with international standards  [25] . It 
contains administrative and identifi cation information (e.g., ID num-
ber, primary source and sender, and seriousness) as well as informa-
tion on the case report (patient characteristics and information on 
suspected and concomitant drugs and ADRs). 
 Study group 
 The Swiss national ADR database VigiFlow was searched for all 
ADR reports from January 1, 1990, until December 31, 2009, cat-
egorized in the System Organ Class (SOC) category No. 1500 (fetal 
disorders) of the WHO-Adverse Reaction Terminology (ART) sys-
tem. This category consists of predefi ned terms of abnormal fetal 
conditions or development occurring during pregnancy or present at 
birth as well as other negative pregnancy outcomes such as induced 
abortion. Cases of drug exposure during pregnancy without negative 
fetal outcome are also included in this category. To restrict the study 
group to relevant cases of fetal disorders, only reports with suffi cient 
information on at least one negative fetal outcome of the SOC1500 
category were included. The exclusion criteria were no information 
on a negative outcome at all, no negative outcome of the SOC1500 
category, or fetal death, intrauterine death, miscarriage, stillbirth, 
abortion, missed abortion, spontaneous incomplete abortion, or 
induced abortion as the only reported outcome. 
 To characterize the study group, the following details from the 
VigiFlow ADR reports were collected: the report year, the sender, 
the sender ’ s report number, the report ’ s seriousness (serious, not 
serious), the reason for seriousness (death, life threatening, hospi-
talization, disabling, congenital anomaly, other), the number and 
types of suspected drugs, the active substance with its Anatomical 
Therapeutic Chemical (ATC) code, the concomitant drugs, the route 
of administration, the reason for drug intake, the date of drug intake, 
the date of the last menstrual period, the reported fetal disorders as 
well as possible neonatal disorders. 
 Analysis 
 The gestational age at the time of drug exposure was calculated 
from the fi rst day of the mother ’ s last menstrual period [weeks post 
menstruation (p.m.), month or trimester]. 
 Fetal disorders were divided into four subcategories: growth retar-
dation, malformations, chromosomal abnormalities, and other fetal 
disorders. The subcategory  “ malformations ” was further categorized 
according to chapter Q of the  International Statistical Classifi cation 
of Diseases, 10  th   Revision , system with respect to the affected organ 
system. 
 The reports ’ quality was assessed by four criteria: ATC code of the 
suspected drug, route of administration, chronology of drug intake, 
and listed ADR. A report ’ s quality was categorized as suffi cient if all 
four criteria were provided. 
 The primary end point was drug exposure (type and number of 
drugs, gestational age) in relation to observed fetal disorders (focus-
ing on malformations). Secondary end points were parameters char-
acterizing the quality of reports (year, sender). 
 Statistics 
 For statistics, the statistical program PASW, version 18, was used. 
For discrete data, relative frequencies were computed. Continuous 
parameters were described by mean, standard deviation (SD), me-
dian, and interquartile range (IQR). Associations between drugs and 
disorders were confi rmed by the likelihood ratio test and the  t- test 
(two-tailed). 
 Results 
 The primary search resulted in 1727 cases, of which 1503 
cases were ruled out by the exclusion criteria. Of the resulting 
224 cases, 16 were excluded as they were incorrectly classi-
fi ed. Another six cases were excluded because they were dou-
ble reports. The fi nal study group, as defi ned by the inclusion 
criteria, therefore included a total of 202 ADR reports from 
the Swiss national ADR database from January 1, 1990 until 
 Table 1  Classifi cations used in VigiFlow. 
Reactions/events (ADRs) WHO-Adverse Reaction Terminology (WHO-ART)  [21] 
Drugs WHO-Drug Dictionary (WHO-DD), with information about active ingredients and ATC codes  [22] 
Medical history/indications WHO  International Classifi cation of Diseases, 10 th  Revision (WHO- ICD-10 )  [23] 
Seriousness International assessment criteria, according to ICH E2A and E2D  [13] 
Causality WHO classifi cation. Further specifi cation in collaboration with the RPVCs: certain, probable, possible, 
unlikely, unclassifi able
 ADRs = Adverse drug reactions, ATC = Anatomical Therapeutic Chemical, ICH = International Conference on Harmonisation, RPVC = Regional 
pharmacovigilance center, WHO = World Health Organization. 
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December 31, 2009, with suffi cient information on at least 
one negative fetal outcome of the SOC1500 category. 
 Reports about fetal disorders have increased considerably 
during the last 20 years (Figure  1 ). Starting from 1991 with 
only one case, the number of reported cases signifi cantly 
increased in 2006, reaching a maximum in 2008 with 31 
reports about fetal disorders. The overall reporting frequency 
in VigiFlow shows that in the general population also, the 
number of ADR reports sent per year has increased during the 
last 20 years (Figure  2 ). 
 Most ADR reports were sent by the Swiss Teratogen 
Information Service (38.6 % ) followed by the RPVCs (37.6 % ) 
and the pharmaceutical companies (21.8 % ); other senders 
played only a minimal role (2.0 % ) (Figure  3 ). 
 Suffi cient quality (as defi ned above) was provided for 
315 of the reported drugs (87.3 % ). The most frequent reason 
for insuffi cient quality was the missing chronology of drug 
intake (6.4 % ) followed by the missing route of administration 
(3.6 % ). Within the study group, 78.7 % of the reports were 
classifi ed as  “ serious ” and 21.3 % as  “ not serious ” . The most 
frequent special reasons for a report to be classifi ed as serious 
were  “ congenital anomaly ” (28.3 % ) and  “ death ” (16.4 % ). 
 Drug exposure 
 A total of 361 suspected drugs were reported in the study 
group. Most women reported only one suspected drug 
(58.9 % ). Two drugs were taken by 22.3 % of the women, 
three drugs were taken by 10.4 % of the women, and four or 
more drugs were taken by 8.5 % of the women. The maximum 
number of suspected drugs reported in a case was nine (mean: 
1.79; SD: 1.31; median: 1.00; IQR: 1). 
 Drugs acting on the nervous system (anatomical main 
group N) were most frequently reported, whereas drugs from 
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 Figure 1  Frequency of reports (n) per year in the study group. 
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 Figure 2  Overall frequency of reports (n) per year in VigiFlow. 
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other anatomical main groups did not differ signifi cantly from 
each other in frequency (Table  2 ). The six most frequently 
reported therapeutic subgroups were psychoanale ptics (N06, 
13 % ), psycholeptics (N05, 12.5 % ), antiepileptics (N03, 
8.6 % ), antivirals for systemic use (J05, 5.5 % ), antiacne prep-
arations (D10, 5 % ), and antibacterials for systemic use (J01, 
4.7 % ). From the pharmacological subgroups, antidepres-
sants (N06A, 12.5 % ), antiepileptics (N03A, 8.6 % ), anxio-
lytics (N05B, 6.1 % ), direct-acting antivirals (J05A, 5.5 % ), 
antipsychotics (N05A, 5.3 % ), and antiacne preparations for 
topical use (D10A, 3.9 % ) were most frequently reported. The 
three most frequently reported chemical subgroups were from 
the nervous system: selective serotonin reuptake inhibitors 
(SSRIs) (N06AB, 6.9 % ), benzodiazepines (N05BA, 6.1 % ), 
and antidepressants excluding SSRIs (N06AX, 4.7 % ). 
 The drug intake per trimester could be assessed for 329 
of the reported 361 drugs; 25.8 % were taken in all three 
Other
0
5
10
15
20
%
 o
f t
ot
al
 re
po
rts
25
30
40
35
Pharm. companies RPVCs
Main groups of senders
STIS
 Figure 3  Frequency of reports ( % ) according to the sender. 
STIS = Swiss Teratogen Information Service, RPVC = Regional phar-
macovigilance center. 
 Table 2  Frequency of anatomical main groups. 
Anatomical main groups. Frequency, n ( % ) 95 % CI
Lower Upper
A Alimentary tract and metabolism   31 (8.6)   5.5   11.4
B Blood and blood-forming organs   10 (2.8)   1.1   4.4
C Cardiovascular system   21 (5.8)   3.6   8.3
D Dermatologicals   28 (7.8)   5   10.5
G Genitourinary system and sex hormones   15 (4.2)   2.2   6.4
H Systemic hormonal preparations (excluding sex hormones and insulins)   10 (2.8)   1.1   4.7
J Antiinfectives for systemic use   41 (11.4)   8.3   14.7
L Antineoplastic and immunomodulating agents   24 (6.6)   4.2   9.7
M Musculoskeletal system   10 (2.8)   1.4   4.7
N Nervous system 145 (40.2)   35.5   45.2
P Antiparasitic products, insecticides and repellents   9 (2.5)   1.1   4.2
R Respiratory system   14 (3.9)   2.2   6.1
V Various   2 (0.6)   0   1.4
Unknown   1 (0.3)   0   0.8
Total 361 (100) 100 100
 CI = Confi dence interval. 
trimesters. Most drugs were consumed in the 1 st trimester 
(85.4 % ), followed by the 2 nd trimester (44.1 % ) and the 3 rd 
trimester (36.5 % ). The drug intake per week of pregnancy 
could be assessed for 284 drugs. It shows a high intake in 
the 1 st trimester, mainly during the fi rst 6 weeks p.m. (range: 
57.7 % – 67.6 % ). In week 7, the drug intake was 50.0 % and 
decreased further afterwards (Figure  4 ). 
 Disorders 
 Among fetal disorders, malformations were most frequently 
reported (68.8 % ) followed by growth retardation (18.3 % ) 
and other fetal disorders (17.8 % ). Chromosomal abnormali-
ties were reported in 6.9 % of the cases (Figure  5 ). In cases of 
malformation, the most frequently affl icted organ system was 
the musculoskeletal system (35.3 % ), followed by the circula-
tory system (25.2 % ). Malformations of the eye, ear, face, and 
neck (15.1 % ), malformations of the urinary system (13.7 % ), 
of the nervous system (12.9 % ), of genital organs (7.9 % ), as 
well as  “ other malformations ” (7.9 % ), cleft lips and cleft 
palates (7.2 % ), and malformations of the digestive system 
(6.5 % ) were reported less often (Figure  6 ). 
 Statistically signifi cant associations between drugs and 
disorders were confi rmed for antibacterials for systemic use 
(J01) and chromosomal abnormalities and fetal death, respec-
tively, as well as for antiepileptics (N03) and malformations 
(in general and particularly of the circulatory system and the 
eye, ear, face, and neck) and neonatal disorders, respectively 
(Table  3 ). 
 Discussion 
 The fi rst study about ADR reports in Switzerland focusing 
on the WHO-ART SOC category No. 1500 (fetal disorders) 
includes all reports of the existing (since 1990) Swiss national 
ADR database. 
Wettach et al., Pharmacovigilance in pregnancy  305
80
70
60
50
40
%
 o
f d
ru
gs
30
20
10
0
0 2 4 6 8 10 12 14 16 18 20
Weeks of pregnancy (p.m.)
22 24 26 28 30 32 34 36 38 40 42
 Figure 4  Drug intake per week of gestation. 
Malformations
Growth retardation
Other fetal disorders
Chromosomal
abnormalities
0 10 20 30 40 50
% of reports
60 70 80
 Figure 5  Type of fetal disorder (frequency,  % ) in reports. 
Musculoskeletal system
Circulatory system
Urinary system
Nervous system
Genital organs
Other malformations
Cleft lip/cleft palate
Digestive system
Respiratory system
0 5 10 15 20 25
% of cases with malformations
30 4035
Eye, ear, face and neck
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 We have been able to show that the number of reports on 
the topic of fetal disorders has increased considerably. This 
may be a result of the development and improvement of the 
reporting system in Switzerland, which is now working much 
more effi ciently than 20 years ago rather than of an increase 
in the appearance of fetal disorders over the years. This inter-
pretation is supported by the overall reporting frequency in 
VigiFlow, which shows that not only in the study group but 
also in general the number of ADR reports sent per year has 
increased during the last 20 years. Not only the number but 
also the quality of the reports has increased with the years. 
For 87 % of the reported suspected drugs, the informational 
content could be classifi ed as suffi cient. Information about the 
time of drug exposure was missing entirely for only 6.4 % of 
the drugs, demonstrating a good overall quality of reports. 
 In almost 60 % of the cases, only one suspected drug was 
reported. This simplifi es the evaluation of the cases regarding 
the association between drug and ADR. The fi nding that an 
association between drugs and fetal disorders was most fre-
quently reported for drugs acting on the nervous system (N) 
(40.2 % of all drugs) has to be interpreted carefully. It does 
not necessarily mean that these drugs are the most dangerous 
ones. If these data are compared with the overall reporting 
frequency in VigiFlow, it becomes obvious that drugs act-
ing on the nervous system (N) are also the most frequently 
reported anatomical main group throughout the general popu-
lation. Drugs acting on the nervous system (N) are widely 
used and, more importantly, are the drug group of primary 
interest concerning ADRs. These factors should be borne in 
mind when drawing conclusions from these data. 
 The fact that 25 % of the drugs were taken during the whole 
pregnancy indicates a high percentage of long-term therapies 
during pregnancy. More drugs were taken in the 1 st trimester 
(85.4 % ) than in the 2 nd (44.1 % ) and the 3 rd (36.5 % ) trimesters. 
Our data are in contradiction with those of other authors who 
have found an increase in the number of exposed women and 
the number of prescribed drugs during pregnancy  [6, 14] . One 
explanation could be that in the other studies only prescribed 
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drugs were assessed while in this study any kind of drug 
intake (including self-medication and medication errors) was 
evaluated. Furthermore, in this study only cases with a nega-
tive fetal outcome, which occurred more frequently after drug 
intake in the 1 st trimester, were analyzed. 
 Malformations were the most frequently reported subcat-
egory of fetal disorders. The circulatory and the musculo-
skeletal systems were the most frequently affected organs, 
suggesting a higher susceptibility compared with other organ 
systems. Our data are in line with data from other sources 
such as from EUROCAT, 2000 – 2008  [8] , or from Sachsen-
Anhalt, Germany, 2008  [9] . 
 The association between antiepileptics (N03) and mal-
formations is widely described in the literature, suggesting 
that antiepileptic drugs (AEDs) (especially valproate but 
also other AEDs such as phenobarbitone, phenytoin, and 
carbamazepine) are potentially teratogenic  [12, 19, 20] and 
that the exposure to AEDs is associated with a two- to three-
fold increased risk for congenital malformations  [12, 18, 24] . 
Data from the North American Antiepileptic Drug Pregnancy 
Registry 2010 show that valproate is associated with a signifi -
cantly higher risk (about twice as high) of malformations than 
other antiepileptics  [17, 26] . In our study group, valproate was 
used in only 15 cases, and we are therefore unable to statisti-
cally describe the effect of valproate alone on the frequency 
or type of malformations. Nevertheless, we have been able 
to demonstrate that the association between antiepileptics 
and malformations is focused on the circulatory system, the 
eye, ear, face, and neck, whereas other authors have earlier 
described an association between antiepileptics and malfor-
mations of the circulatory system only  [18 – 20] . 
 Conclusions 
 A substantive amount of information on pharmacovigilance 
has been gained from the Swiss national ADR database ’ s 
reports associated with fetal disorders. 
 Our results have demonstrated the important relationship 
between drugs acting on the nervous system and malforma-
tions of the circulatory system as well as the relationship 
between nervous system drugs and malformations of the eye, 
ear, and neck. It is hoped that this study will lead to further 
prospective pharmacoepidemiological and pharmacovigi-
lance studies confi rming these results. 
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